评估酸引起的系统损伤:FAERS对不良事件的全面分析
Zhaojun Wang1, Xin Su2, Donglei Shi1
1Department of Thoracic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
BMC cancer
|December 18, 2024
概括
龙酸 (ZA) 的使用与各种脏和尿路不良事件 (AE) 有关,其中管性瘤是最常见的. 根据特定的癌症或骨质疏松症征兆,监测这些副作用至关重要.
科学领域:
- 药监和药物安全 药监和药物安全
- 腎臟病學 (nephrology) 是一種醫學專業.
- 在瘤学瘤学.
背景情况:
- 佐乐龙酸 (ZA) 是骨转移和骨质疏松症的关键治疗方法.
- 功能障碍是已知与ZA相关的不良事件之一.
- 本研究使用FDA数据调查了与ZA相关的和尿路不良事件 (AE).
研究的目的:
- 为了识别和量化脏和泌尿系统不良事件 (AE) 与龙酸 (ZA) 相关.
- 分析这些AE在ZA使用的不同适应症中.
- 为ZA治疗的临床监测策略提供信息.
主要方法:
- 利用美国FDA不良事件报告系统 (FAERS) 数据库从2004年第一季度到2024年第一季度.
- 采用统计方法,包括报告几率比率 (ROR),以检测有意义的AE.
- 应用多个算法 (ROR,PRR, BCNN,MGPS) 进行可靠的AE量化.
主要成果:
- 确定了52,495份AE报告,其中ZA是主要的可疑药物.
- 已识别出25种不同的脏和尿路副作用,其中管性瘤是最常见的.
- 具体的副作用因适应症而异:管亡 (乳腺癌,骨质疏松症),原性糖尿病无味 (肺癌),蛋白尿 (多发性骨髓瘤),多发性尿 (前列腺癌).
- 大多数AE发生在ZA使用360天后,第二次峰值在30天内发生.
结论:
- 药监督数据突出显示,需要针对脏和尿路AEs与佐勒龙酸进行量身定制的监测.
- AE监测应以ZA所规定的特定适应症为指导.
- 积极管理ZA相关的毒性对于患者的安全至关重要.
相关概念视频
Renal Failure: Dose Adjustments
63
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
63
Factors Affecting Renal Clearance: Renal Impairment
53
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
53
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
Heart Failure Drugs: Diuretics
339
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
339


